This is a double-blind randomized controlled study. The study will last up to 16 weeks from the initial phone screen (it could take up to eight weeks to schedule and complete the initial screening process and schedule the 2 MRI visits). Once subjects have completed the screening process, they will begin the 8-week trial phase. Subjects will be assessed weekly throughout the study for efficacy and tolerability.
The investigators plan to recruit 80 participants with emotional dysregulation (ED) in the treatment arm. In addition, the investigators will aim to recruit 40age-, sex-, and parental-education matched participants without emotional dysregulation, and major psychopathology as Typically Developing (TD) control participants in the control arm.
Upon scheduling the baseline visit, only the emotional dysregulation (ED) participants will be randomized 1:1 to be exposed to NAC or placebo treatment for 8 weeks. Participants will complete baseline and post-treatment (endpoint) brain MRI acquisition. TD participants will complete the same screening and characterization process as the ED group and then will be invited to complete MRI eligibility screening and to be scanned twice, separated by an eight-week interval, but the TD will not complete the NAC treatment or receive a placebo. See Table 1 (Study Schema) for a complete list of characterization measures to be completed by each group.

开始日期2027-01-01

申办/合作机构

The Massachusetts General Hospital

[+1]

NCT04381897

/ Not yet recruiting临床2期IIT

Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study

This research project is a randomized cross-over pilot trial which aims to test the efficacy of N-acetylcysteine (NAC) for the treatment of Repetitive Behaviors (RB) and self-injurious behavior (SIB) in patients with Cornelia de Lange Syndrome (CdLs).
NAC is a known anti-oxidative stress and neuroprotective agent, which has been shown to decrease the occurrence of SIB such as skin picking. NAC has also shown partial response in trials for compulsive behaviors in Obsessive Compulsive Disorder (OCD) and related disorders in autism.
Cornelia de Lange syndrome (CdLS) is a genetic disorder with autistic features, including RBs and SIB. In this randomized clinical trial, participants with CdLS will be blindly assigned one of two possible treatment arms: 1) placebo (8 weeks) and NAC (8 weeks); or 2) NAC (8 weeks) and placebo (8 weeks), with an intermediate 2-week washout period.

开始日期2026-11-01

申办/合作机构

The Johns Hopkins University

NCT07227649

/ Not yet recruiting临床2期IIT

NAC-REPAIR: N-Acetylcysteine-facilitated Redox-Immune Modulation for Post-surgical Analgesia and Injury Recovery

This pilot asks whether peri-operative N-acetylcysteine (NAC) improves recovery after common outpatient hand/foot-ankle surgery-specifically, does NAC reduce pain and opioid use and enhance function by modulating redox-inflammatory pathways? Primary objectives are to establish feasibility (accrual, adherence, follow-up), estimate NAC vs placebo effects on pain, function, and opioid consumption, and characterize inflammatory signatures that may predict response.
Methods: a single-site, double-blind, 1:1 randomized trial (N≈80) comparing NAC 1,200 mg twice daily for 14 days (starting pre-op) vs matching placebo; daily e-diaries for POD0-14; standardized outcomes (PROMIS Pain Interference; QuickDASH or FAAM; PGIC; opioid MME); and small blood draws pre-surgery and at two follow-up visits for cytokine profiling.

开始日期2026-10-15

申办/合作机构

University of Arizona

[+1]

100 项与乙酰半胱氨酸相关的临床结果

登录后查看更多信息

100 项与乙酰半胱氨酸相关的转化医学

登录后查看更多信息

100 项与乙酰半胱氨酸相关的专利（医药）

登录后查看更多信息

32,979

项与乙酰半胱氨酸相关的文献（医药）

2026-12-31·DRUG DELIVERY

Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

Review

作者: Huitema, Alwin D R ; O'neill, Allison F ; Bleyer, Archie ; Streefkerk, Nienke ; Bouffet, Eric ; Sullivan, Michael ; Masroor, Amirhossein ; Fresneau, Brice ; Maibach, Rudolf ; Van Grotel, Martine ; Hoetink, Alexander E ; Rajput, Kaukab M ; Papadakis, Vassilios ; Knight, Kristin ; Brock, Penelope R ; Geller, James I ; Kogner, Per ; Ansari, Marc ; Veal, Gareth J ; Van Den Heuvel-Eibrink, Marry M

Cisplatin-induced hearing loss (CIHL) in pediatric cancer patients is an irreversible and highly prevalent adverse effect with a devastating impact on quality of life. Sodium thiosulfate (STS) has recently been approved for systemic administration as an otoprotective agent in children. However, implementation of systemic STS has its challenges, and there is currently limited evidence to support local STS for children. This review investigates the potential value of locally administered otoprotective agents other than STS with a focus on future pediatric implementation. We conducted a systematic review on the efficacy and safety of locally applied non-STS otoprotective agents in in vivo settings. This included a summary of investigated drug delivery methods and administration routes. We identified 70 preclinical and eight clinical studies. Agents were categorized based on their biological mechanisms: anti-inflammatory, chemical deactivators, calcium blockers, biologicals, and miscellaneous mechanisms. Preclinical studies investigated 45 different agents. Dexamethasone and N-acetylcysteine were identified as efficacious agents recurrently and progressed to clinical trials. Dexamethasone was investigated in three randomized clinical trials (RCTs) and three non-randomized clinical studies and showed statistically significant but not clinically relevant benefit in two trials. N-acetylcysteine was investigated in two clinical trials and one RCT and was minimally effective in the RCT and in one clinical study. Our review did not identify available studies of local alternative otoprotective agents that could reliably replace systemic STS in terms of safety and efficacy for pediatric patients. Further research on the optimal dosage, delivery method, and timing of otoprotective agents is needed.

2026-12-31·CNS oncology

Arginine deprivation induces prolonged autophagy activation and ROS-dependent cell death in glioblastoma multiforme

Article

作者: El-Jawhari, Yasmin ; Saad, Rawan ; Sarieddine, Majd ; El-Husseini, Nour ; El-Sibai, Mirvat ; Abi-Habib, Ralph J. ; Shaheen, Maha ; Abdelkhalek, Maya

BACKGROUND:

Arginine deprivation was shown to be selectively cytotoxic to GBM cells with cell death being caspase-independent, non-apoptotic. In this study, we assess the impact of prolonged arginine deprivation on GBM cells, the potential activation of autophagy, the mechanism of its activation, and its impact on cell cytotoxicity.

METHODS:

GBM cell lines A172 and U251 were used in this study and arginine deprivation was induced by a cobalt-substituted, PEGylated human arginase I [HuArgI (Co)-PEG5000].

RESULTS:

Arginine deprivation induced prolonged cytotoxicity up to 120 hours post-treatment. Cytotoxicity persisted despite cells overexpressing ASS-1. Arginine deprivation also induced a marked and sustained activation of autophagy, starting at 24 hours and lasting up to 120 hours post-treatment. Autophagy was shown to induce cell death since its inhibition by chloroquine significantly decreased cytotoxicity, indicating that the extensive activation of autophagy is resulting in cell death of GBM cells. Moreover, ROS was shown to accumulate in treated cells and neutralizing ROS using NAC did not affect the autophagic response but led to a complete reversal of cytotoxicity, demonstrating that death by autophagy is dependent on ROS generation.

CONCLUSION:

Arginine deprivation leads to sustained activation of autophagy and subsequent ROS-dependent cell death in GBM cells.

2026-12-31·Journal of the International Society of Sports Nutrition

A comprehensive review of the physiology and evidence base to guide the use of ergogenic and medical supplements for enhanced cycling performance

Review

作者: Prieto-Bellver, Gorka ; Edwards, Sophie ; Cornelisse, Erik ; Rowland, Angela ; Rowland, Andrew ; Hopkins, Ashley M ; Karapetis, Christos S ; Menz, Bradley ; Wallen, Matthew P

BACKGROUND:

A growing body of evidence supports the use of supplements to enhance cycling performance through both direct and indirect mechanisms.

METHODS:

This review was informed by a structured literature search conducted in PubMed, Scopus and Web of Science for peer-reviewed studies published up to May 2025. Studies were included if they involved human participants, were published in English and evaluated outcomes related to endurance performance, recovery or physiological function.

RESULTS:

Direct enhancement with ergogenic supplements is primarily achieved via modulation of skeletal muscle energy metabolism. During exercise, adenosine triphosphate (ATP) resynthesis is driven by the phosphagen system, glycolysis, oxidative phosphorylation and beta-oxidation, with each system contributing according to the intensity and duration of the effort. Supplements such as beta-alanine, caffeine, carbohydrates, carnitine, creatine monohydrate, dietary nitrates, electrolytes, exogenous ketones, N-acetylcysteine and sodium bicarbonate support these energy systems by improving substrate utilization, buffering capacity, energy availability or resistance to fatigue. In addition to ergogenic supplements that directly enhance performance, medical supplements play an important indirect role by supporting bone health, connective tissue integrity, inflammation management, micronutrient status, muscle repair and gut function. Evidence-based options for cyclists include calcium, cherry juice, collagen, curcumin, iron, multivitamins, omega-3 fatty acids, pickle juice, probiotics, protein, vitamin C, vitamin D and zinc. Each contribute to either improved recovery, immune support or long-term physiological adaptation. Evidence quality varied substantially across supplements, with strongest support for Australian Institute of Sport (AIS) Group A compounds. The integration of physiological testing including assessments of maximal oxygen consumption (VO₂max), lactate threshold, metabolic substrate utilization and blood biomarkers may inform the development of individualized supplementation strategies tailored to training demands and competitive goals.

CONCLUSIONS:

This evidence-informed approach underscores the synergistic relationship between nutrition, training and performance optimization in cycling. Future research should explore personalized nutrition frameworks, interactions between multi-supplement protocols and the molecular mechanisms underpinning adaptation to endurance training and nutritional interventions.

784

项与乙酰半胱氨酸相关的新闻（医药）

2026-08-14

·药通社

扬子江首款，申报临床！

2026年8月13日，扬子江的2.2类YR-2316吸入粉雾剂，临床申请获受理。扬子江目前尚无一款吸入粉雾剂获批，目前在研的仅有一款仿制茚达特罗格隆溴铵吸入粉雾剂，进度尚早，吸入粉雾剂创新对于扬子江来说属于全新领域。但这款YR-2316吸入粉雾剂，企业尚未对外介绍，具体信息未知。扬子江在吸入领域起步相对较晚，截至目前，仅有2款吸入制剂获批，都是吸入溶液。第一款是盐酸左沙丁胺醇雾化吸入溶液，2022年11月获批；第二款是吸入用乙酰半胱氨酸溶液，2024年4月获批。除此之外，仅剩1款吸入溶液报产——瑞维那新吸入溶液，扬子江于2026年7月1日获受理，正好成为第五十家报产的企业。扬子江，第50家企业抢首仿可见扬子江在吸入板块的布局较慢，而吸入粉雾剂更是首次踏足。吸入剂根据装置的区别分为：吸入粉雾剂、吸入气雾剂、吸入喷雾剂、吸入液体制剂。中国吸入制剂中雾化溶液占比最大，其中布地奈德混悬液销售额曾达到73亿人民币；粉雾剂占比25%左右，气雾剂占比最少。2015-2024年，中国公立医院吸入制剂终端销售额从140多亿元增长到280多亿元。吸入粉雾剂属于高难度制剂，难度主要在于： 1、吸入制剂是药械组合产品，其药械一体化构筑了极高的技术壁垒，粉雾剂需要有特制的干粉吸入装置，由患者主动吸入雾化药物至肺部，研发过程中对药物粒径，药物分散状态，与载体的结合，药械结合，定量释放等都要求极高。 2、吸入制剂药物和给药装置一体，对患者的操作协作性要求较高，操作熟练度会影响个体吸入效果，操作不当容易会导致BE实验结果受到影响，监管机构对BE实验和临床实验要求也较为严苛。 3、能生产粉雾剂的产线非常少，核心设备基本依赖进口，价格昂贵，对生产人员和质量控制人员要求都极高。粉雾剂药物粒径在微克级别，对误差的容忍度小，因此批量化生产的过程中，很容易出现不稳定的现象。总的来说，这是一个同时具备制剂工艺壁垒、装置壁垒、临床壁垒、监管壁垒，四大壁垒的领域，技术难度很大。在此情况下，国内药企踏足的普遍较晚，还屡屡碰壁，直至目前能做的企业也比较少。国内首家获得突破性进展的是健康元，2024年6月4日沙美特罗替卡松吸入粉雾剂4类获批，这是国内整个行业第一个过评的吸入粉雾剂。而在此之后，国产的吸入粉雾剂就开始迅速发展，目前已经获得进展的国产企业包括—— 四川普锐特药业（沙美特罗替卡松吸入粉雾剂，国产第二家）；欧米尼医药（沙美特罗替卡松吸入粉雾剂，国产第三家）；润生药业（丙酸氟替卡松吸入粉雾剂，国内首家/独家）山东京卫制药（噻托溴铵吸入粉雾剂，国内首家过评）；正大天晴（噻托溴铵吸入粉雾剂，国产第二家过评）。重磅：京卫制药副总经理兼研究院执行院长-孙迎基院长将出席9月4-5日【吸入制剂大会】，并分享噻托溴铵吸入粉雾剂成功获批经验，十年磨一剑，经验之谈不容错过。扫码查看议程、免费报名报名后还可免费解锁1v1约见同时更具历史意义的是，国内的吸入粉雾剂也在今年获得了FDA的认可，成功叩开了国际主流市场大门。美国时间2026年1月12日，润生药业的“沙美特罗替卡松吸入粉雾剂”成功获FDA批准上市，成为有史以来首个成功出海美国的中国自研吸入粉雾剂。可以见得的是，国内吸入粉雾剂发展速度很快，但仍存在诸多落后。比如国内市场最大的吸入粉雾剂，布地奈德福莫特罗吸入粉雾剂，至今还没有国内企业攻克，仍是阿斯利康独占市场。图源：摩熵医药阿斯利康在国内吸入粉雾剂市场上断层第一，正是归功于这个品种，十年累计市场超200亿。然而，这款粉雾剂至今国内还无企业挑战成功，有进度的企业是： 1、上海新黄河制药有限公司，完成Ⅲ期临床后，2025年2月以4类仿制报产获受理，目前处于补充资料暂停阶段； 2、杭州畅溪制药有限公司，2026年4月以2.2类改良报产获受理，这家公司做的是吸入式胶囊（每粒胶囊装一次剂量的药粉，使用前装入吸入器，装置内刺针将胶囊刺破，患者吸气时药粉随气流进入肺部）。 CXG87（布地奈德福莫特罗吸入粉雾剂（IV）胶囊型）Ⅲ期临床研究结果显示，CXG87在用药42天后，达到主要终点，疗效非劣于阳性对照药信必可®都保®，受试者肺功能改善明确，在哮喘症状缓解和哮喘急性发作频次降低等方面均呈现出较好的趋势，且整体安全性与信必可®都保®相当。同时，亚人群（吸气能力相对较弱的哮喘患者）的临床获益对比显示，CXG87可适用的吸气流速范围较大，覆盖哮喘患者人群更广泛。畅溪制药创始人对此表示，CXG87通过对经典吸入产品的重新设计，显著降低产品的气流依赖性，并在一定程度上改善了可操作性和使用稳定性。如果获得批准，CXG87将帮助哮喘患者，尤其是气流受限（如吸气流速较低或肺活量较小）的患者获得更好的哮喘控制效果，以及更好的治疗体验。 3、除此之外，还有山东京卫、珠海瑞斯普利，两家企业获批临床。图源：摩熵医药布地奈德福莫特罗粉雾剂是一款药械组合产品，化合物专利早已到期，但阿斯利康采用的Turbuhaler®DPI装置，是干粉吸入领域最具特殊的装置之一，该装置由13个塑料部件和一个钢弹簧组成，有一个可能包含50、100或200剂量活性药物/API的储库，技术壁垒很高。这对于国内企业来说也是一座难以逾越的高山，希望早日有好消息传来。吸入粉雾剂药械一体的高壁垒，依然横亘在众多国内药企面前。处方工艺、给药装置、BE / 临床研究、放大生产，任意一环出错，都可能让项目止步。国内企业如何跨过技术、装置、监管多重门槛，实现吸入粉雾剂从研发到申报、再到出海的全流程落地？ 9 月 4‑5 日，吸入制剂大会将聚焦行业真实痛点。扫码查看完整议程，即可免费报名参会，报名成功还可解锁嘉宾 1v1 约见机会，面对面交流项目卡点。多场核心行业论坛免费对外开放，无需付费即可入场学习交流。 👉扫码进入会议小程序查看同期所有论坛全议程本届展会彻底重构往届对接模式，依托全新升级的1V1约见系统，打造会前、会中、会后全流程闭环的深度对接服务，直击“找品种、找资本、找供应链、找海外渠道”匹配难、沟通浅的行业痛点：重磅企业矩阵特设10间专属对接房，每间入驻一家行业标杆企业。助您一站式锁定产业链关键节点。 *重磅企业持续增加中，敬请期待... 甲方需求直连现场发布真实甲方企业需求清单，涵盖原料药采购、创新管线授权、CXO合作、投融资及设备耗材采购等方向，让合作诉求一目了然。 *上下滑动查看 *以上为部分公司呈现，排名不分先后... 嘉宾面对面洽谈汇聚产业决策层与学术带头人，为您提前勾勒现场高端人脉网络。 *嘉宾排名不分先后，按姓名首字母排序，持续增加中... 自由约见，高效会晤所有参会人员均可通过1V1约见系统自由发起洽谈邀约。系统基于智能匹配机制，特别针对合成生物学、CGT、中药、宠物药等热门细分赛道设立专属匹配通道，集中汇聚同赛道供需双方，让企业高效锁定垂直领域的关键合作伙伴。到场即直面精准匹配的决策层，大幅提升转化效率，精准实现“找方向、搞增长、寻长期战略伙伴”的目标。 👉扫码进入会议小程序报名后即可约见

2026-08-12

·BioSpace

Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study

TORONTO, ON / ACCESS Newswire / August 12, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today announced positive results from a research study conducted by Defence Research and Development Canada - Suffield Research Centre ("DRDC") evaluating bucillamine in an established animal model of nerve-agent exposure. The study compared bucillamine with N-acetylcysteine ("NAC"), an antioxidant previously evaluated in this research model. The objective was to examine clinical signs, seizure activity and the preservation of GABA receptor signaling in the brain following exposure. Animals pretreated with either bucillamine or NAC demonstrated preservation of hippocampal GABA receptor post-synaptic density compared with control animals. Bucillamine appeared comparable to NAC on this measured endpoint. All study groups displayed similar signs of seizure activity and other clinical effects associated with exposure. Importantly, no pulmonary hemorrhage was observed in the bucillamine-treated group, whereas it was observed in the NAC-treated group. No signs of cerebral hemorrhage were observed in either group. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); "The DRDC research study provides a scientific basis for continuing to evaluate bucillamine in combination with established treatments for nerve-agent exposure," said Michael Frank, Chief Executive Officer of Revive. "Bucillamine demonstrated preservation of the measured GABA receptor endpoint comparable to NAC, while pulmonary hemorrhage observed in the NAC-treated group was not observed in the bucillamine-treated group. These findings support our broader objective of evaluating bucillamine's potential role in biodefence and pandemic preparedness, and we intend to explore further related opportunities with government, defence, and other strategic organizations." DRDC will continue its research on bucillamine through additional confirmatory studies scheduled to begin in Q4-2026. Additional research will evaluate its potential effects on brain injury, oxidative stress, response to standard treatment and respiratory function. In addition, the current research findings and further research may help Revive evaluate potential development, funding, and collaboration opportunities with government, defence, and strategic organizations. About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. For more information, visit . For more information, please contact: Michael Frank Chief Executive Officer Revive Therapeutics Ltd. Tel: 1-888-901-0036 Email: mfrank@revivethera.com Website: SOURCE: Revive Therapeutics Ltd. View the original press release on ACCESS Newswire

临床结果

2026-08-10

·Med专业晩讯

医药晚讯-2026.08.10星期一

大家晚上好，这里是Med专业晚讯——只做最新的医药资讯，日更不辍。商业动态层面，百济神州引进4款RAS抑制剂亚洲权益并同步淘汰低效管线，甘李药业博凡格鲁肽欧洲授权落地Menarini总金额超7亿欧元，威高血净与霍德生物分别完成了并购和C轮融资。创新药方面，石药创新猴痘mRNA疫苗获FDA批准，RiboX环状RNA体内CAR-T获FDA IND批准为全球首款，ST人福舒芬太尼获批分娩镇痛临床，莱美药业吸入用乙酰半胱氨酸获注册证书。前沿动态方面，诺和诺德、中科院、阳药科大学团队都有新的文章发表。AI与制药层面，诺和诺德与AWS达成战略合作，晶蛋生物AI离子通道平台获Almirall超2.5亿欧元海外授权，深度细胞完成近亿元种子轮融资。商业动态 1. 第一三共将奎扎替尼在中国大陆的独家推广权授予信达生物，填补高危白血病一线靶向治疗空白。8月10日第一三共宣布将二代FLT3抑制剂维复泰®（奎扎替尼）在中国大陆的独家推广权益授予信达生物。该药是目前国内唯一获批用于新诊断FLT3-ITD突变急性髓系白血病的一线靶向药物，III期临床显示中位总生存期达31个月，显著优于传统化疗。 2. 百济神州引进4款RAS抑制剂亚洲权益，资源聚焦高价值肿瘤靶向资产。8月10日，百济神州与Revolution Medicines达成合作，引进4款临床阶段RAS小分子抑制剂的亚洲权益，同时推进与自有PRMT5抑制剂及三特异性抗体的联合用药全球III期临床。为聚焦资源，百济神州同步淘汰了低效早期管线。 3. 甘李药业博凡格鲁肽欧洲授权落地Menarini，总交易金额超7亿欧元。甘李药业宣布将双周长效GLP-1博凡格鲁肽欧洲独家权益授予意大利Menarini集团，首付款6200万欧元，潜在总交易额超7亿欧元（约合58亿元人民币）。该产品为全球进度领先的双周减重GLP-1，甘李药业保留了代谢适应症海外开发权，是国产创新药出海的重要里程碑。 4. 威高血净85亿并购威高普瑞过会，打造"血液净化+医药包材"双轮驱动。8月10日，威高血净以85.11亿元收购威高普瑞100%股权的交易获上交所重组委通过。威高普瑞为国内预灌封注射器龙头，市占率超50%，2025年营收18.84亿元、净利润6.01亿元。交易完成后将形成"血液净化+医药包材"双轮驱动。 5. 霍德生物完成近2亿元C轮融资首关，加速iPSC细胞治疗临床开发。8月10日，霍德生物宣布完成近2亿元C轮融资首关，由天士力资本、海邦投资、广州健康产投及老股东隆门资本共同参与。资金将用于加速多适应症临床开发及商业化生产准备。霍德生物在iPSC衍生通用型细胞治疗领域建立了从基因编辑到规模化的全链条技术平台。创新药进展 1. 石药创新猴痘mRNA疫苗获美国FDA临床试验批准。8月10日，石药创新公告，控股子公司巨石生物与中国科学院微生物研究所合作开发的SYS6037注射液（猴痘mRNA疫苗）获得美国FDA批准，可在美国开展临床试验。这是国内mRNA疫苗技术平台国际化的重要进展。 2. RiboX Therapeutics环状RNA体内CAR-T获FDA IND批准，全球首款原位CAR-T临床管线诞生。近日，RiboX Therapeutics宣布其环状RNA体内CAR-T候选药物RXIM002获得FDA IND批准，为全球首款环状RNA原位CAR-T临床管线。RXIM002将同步推进自身免疫性疾病和实体瘤两个适应症的临床开发。 3. ST人福枸橼酸舒芬太尼注射液获批开展分娩镇痛临床试验。8月10日，ST人福公告，枸橼酸舒芬太尼注射液获NMPA批准开展分娩镇痛临床试验。舒芬太尼为临床常用强效阿片类镇痛药，此次获批是公司在麻醉镇痛产品线向围产期医学领域的重要延伸，若后续顺利获批将丰富其麻醉领域产品组合。 4. 莱美药业吸入用乙酰半胱氨酸溶液获药品注册证书。8月10日，莱美药业公告，吸入用乙酰半胱氨酸溶液获NMPA签发的药品注册证书。该药为临床常用祛痰药物，适用于多种呼吸系统疾病引起的咳痰困难，吸入给药起效快、副作用小，市场稳定且规模可观，将丰富公司在呼吸科领域的产品梯队。技术前沿 1. Nature Medicine(IF=52.5/Q1): 诺和诺德团队提出糖尿病前期缓解新框架，重塑T2D全生命周期预防策略。诺和诺德团队提出将T2D预防重新定义为以糖尿病前期缓解为核心目标，构建了涵盖发育、过渡和情境决定因素的T2D生命全程风险架构，明确代谢脆弱性加剧和血糖恢复的关键窗口，确定了T2D预防十大优先事项，主张在生命早期介入以改变疾病自然进程。 Type 2 diabetes prevention across the life course 2. Biomaterials(IF=13.6/Q1): 中科院团队开发超声控释NO纳米平台，实现牙周炎精准按需治疗。中科院团队开发了基于临床NO供体ISDN的超声控释平台，通过低强度超声激发实现NO按需释放，发挥强效抗菌抗生物膜作用并抑制NLRP3炎症通路。大鼠模型显示治疗显著降低细菌载量、缓解炎症并维持牙槽骨结构，为牙周炎精准治疗提供了高转化前景策略。 Ultrasound-induced nitric oxide release from isosorbide dinitrate nanoparticles for on-demand therapy of periodontitis 3. Journal of Controlled Release(IF=12.4/Q1): 沈阳药科大学提出集成药物-器械系统工程框架，推动精准给药自主化。沈阳药科大学团队综述中，系统定义集成药物-器械系统为以系统控制平台实现临床级治疗自主化的给药架构，围绕机械自主性、可编程释放及监测-决策整合三大支柱展开，并提出成熟度分级模型和AAC评估框架，为药物-器械集成系统开发提供路线图。 Engineering integrated drug–device systems for autonomous administration, programmable release, and therapeutic control( DOI: 10.1016/j.jconrel.2026.115241) AI与制药 1. 诺和诺德与AWS达成战略合作，AI驱动药物发现加速研发进程。8月10日，诺和诺德与亚马逊云科技宣布建立战略合作，利用智能体AI和云技术加速药物发现并推进运营现代化。双方在伦敦联合设立创新中心，致力于缩短从确定药物靶点到首次人体给药的研发周期。传统制药巨头与顶尖云服务商的深度绑定，有望将AI技术系统性地嵌入药物研发全链条。 2. 晶蛋生物与Almirall达成合作及许可协议，AI驱动离子通道平台实现海外技术输出。8月10日，晶蛋生物宣布与西班牙Almirall达成合作及许可协议，双方将基于晶蛋生物AI驱动的离子通道小分子药物发现平台，结合Almirall在医疗皮肤领域的研发能力，共同推进一款医学皮肤科小分子创新药研发。潜在总交易金额最高约2.545亿欧元，此次合作标志着国产AI制药技术平台实现海外输出，验证了平台的技术价值。 3. 深度细胞完成近亿元种子轮融资，AI驱动分子设计平台获资本青睐。近日，AI制药企业深度细胞完成近亿元种子轮融资，由中科创星、顺禧基金、千骥资本等共同投资。公司以分子相互作用智能基座模型为核心，构建高精度分子设计平台，可精准预测蛋白质-小分子等生物分子相互作用。种子轮即获近亿元融资，凸显市场对AI制药赛道的持续看好。友情提示：本文整理资讯仅作为交流参考，不构成投资建议。喜欢的话，请关注并点击 "爱心“，并将公众号设为”星标“ 第一时间获取最新动态

100 项与乙酰半胱氨酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00221	乙酰半胱氨酸	V03AB23 S01XA08 R05CB01	DB06151

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
支气管炎	中国	精鼎医药研究开发（上海）有限公司	2025-05-13
嵌甲	日本	Maruho Co., Ltd.	2023-03-27
对乙酰氨基酚过量	澳大利亚	Pfizer Australia Pty Ltd.	2006-07-17
慢性阻塞性肺疾病	中国	江苏吉贝尔药业股份有限公司	1985-01-01
哮喘	日本	Sannova KK	1965-01-05
支气管扩张	日本	Sannova KK	1965-01-05
慢性支气管炎	日本	Sannova KK	1965-01-05
囊性纤维化	日本	Sannova KK	1965-01-05
喉炎	日本	Sannova KK	1965-01-05
咽炎	日本	Sannova KK	1965-01-05
肺炎	日本	Sannova KK	1965-01-05
肺气肿	日本	Sannova KK	1965-01-05
肺结核	日本	Sannova KK	1965-01-05
药物性肝损伤	美国	Apothecon LLC	1963-09-14
肝损伤	美国	Apothecon LLC	1963-09-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性支气管炎	临床3期	中国	Zambon SpA	2019-06-21
急性支气管炎	临床3期	中国	Zambon Switzerland Ltd.	2019-06-21
特发性肺纤维化	临床3期	比利时	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	法国	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	德国	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	意大利	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	荷兰	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	西班牙	Zambon SpA	2000-03-01
特发性肺纤维化	临床3期	英国	Zambon SpA	2000-03-01
普通感冒	临床2期	加拿大	Novartis AG	2015-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04627922 (NAC_CUD-TUD, CTgov)	临床4期	烟草依赖 \| 大麻滥用 \| 未指明的药物依赖	41	Cognitive behavioral therapy (CBT)+N-Acetyl cysteine (N-acetyl Cysteine (NAC) & Cognitive Behavioral Therapy)	蓋顧艱遞鏇構廠顧繭鏇(鑰選壓遞蓋糧憲觸襯積) = 遞鬱餘齋窪鏇壓遞製襯襯網襯艱鹽憲窪餘鑰衊 (蓋窪膚窪獵築觸遞簾憲, 10.91) 更多	-	2026-08-11
				Placebo comparator (Placebo Comparator: Placebo & Cognitive Behavioral Therapy)	蓋顧艱遞鏇構廠顧繭鏇(鑰選壓遞蓋糧憲觸襯積) = 膚鹹築蓋築鑰鑰繭積醖襯網襯艱鹽憲窪餘鑰衊 (蓋窪膚窪獵築觸遞簾憲, 11.52) 更多
NCT03822637 (ENACT, CTgov)	临床4期	哮喘	4	N-Acetylcysteine (NAC) (20% N-Acetylcysteine (NAC))	簾簾鬱蓋夢齋鑰範窪願(憲夢鏇鏇齋廠廠壓構襯) = 餘遞積觸壓膚築築獵膚廠鬱淵夢衊鏇顧鬱鏇鑰 (繭選願顧齋糧顧積網餘, 3.74) 更多	-	2026-06-11
				Placebo+NAC+albuterol (Placebo)	簾簾鬱蓋夢齋鑰範窪願(憲夢鏇鏇齋廠廠壓構襯) = 鏇糧網襯遞願簾鑰鏇鏇廠鬱淵夢衊鏇顧鬱鏇鑰 (繭選願顧齋糧顧積網餘, 6.49) 更多
NCT04481048 (DoDNAC, CTgov)	临床2期	神经纤维瘤病1型	25	N-Acetyl cysteine (N-Acetylcysteine (NAC))	獵構製鹽膚壓廠鬱艱網(製範鹹遞築壓鹽糧鏇製) = 糧廠鹹膚構憲範顧膚範醖壓積願選鏇範願鑰醖 (範範襯顧壓製鑰糧網鬱, 9.3) 更多	-	2026-06-05
				Placebo (Placebo)	獵構製鹽膚壓廠鬱艱網(製範鹹遞築壓鹽糧鏇製) = 範積糧築蓋壓獵簾繭淵醖壓積願選鏇範願鑰醖 (範範襯顧壓製鑰糧網鬱, 12.7) 更多
NCT03220776 (Pubmed \| Transl Psychiatry)	临床2期	酒精使用障碍	54	N-acetylcysteine (NAC)	築窪壓鏇衊構衊壓廠獵(繭選網鏇築壓選廠鹹鹹) = 製艱鏇憲夢壓構製襯襯襯壓獵夢齋襯觸獵範膚 (夢觸獵獵廠獵憲鬱憲膚, 4.6) 更多	积极	2026-06-03
				Placebo	築窪壓鏇衊構衊壓廠獵(繭選網鏇築壓選廠鹹鹹) = 鬱製積襯憲製襯鏇選廠襯壓獵夢齋襯觸獵範膚 (夢觸獵獵廠獵憲鬱憲膚, 4.55) 更多
DDW2026	N/A	酒精性肝炎	10,248	NAC+steroid	蓋夢鏇遞壓願糧夢糧築(淵繭鏇鏇窪淵繭齋製範) = the incidence of HRS/ARF and MALOs was comparable between groups at 1,3,6, and 12 months 積鏇鬱淵鹽願積蓋範積 (築壓餘窪廠製網簾顧襯 ) 更多	不佳	2026-05-02
				steroid only
NCT06581783 (Pubmed \| J Gastroenterol Hepatol)	N/A	-	1,200	Placebo	構餘鑰積製廠鹽窪簾觸(蓋艱壓觸艱蓋廠觸獵齋) = 遞遞簾廠顧構鏇膚蓋鏇餘鏇蓋遞壓鬱醖糧鏇襯 (壓製廠鑰壓齋願衊壓鏇 ) 更多	积极	2026-04-10
				Simethicone + NAC (premedication to endoscopy interval of 10-20 min)	構餘鑰積製廠鹽窪簾觸(蓋艱壓觸艱蓋廠觸獵齋) = 積憲憲蓋鬱選願廠醖鹽餘鏇蓋遞壓鬱醖糧鏇襯 (壓製廠鑰壓齋願衊壓鏇 ) 更多
NCT03911414 (CTgov)	临床4期	膳食补充剂 \| 抑郁症 \| 情绪不稳 ... 更多	27	Omega-3 Fatty Acids+Inositol (Omega-3 Fatty Acids + Inositol)	齋網積構膚艱衊襯構艱(積齋壓齋膚鏇壓齋築構) = 糧鬱鏇鏇遞製獵糧簾膚衊範膚鏇構夢膚製齋壓 (鏇遞製壓簾糧膚艱願淵, 5.5) 更多	-	2026-03-18
				Open-label Treatment with N-acetylcysteine (N-acetylcysteine)	齋網積構膚艱衊襯構艱(積齋壓齋膚鏇壓齋築構) = 簾艱鏇鹹鹹餘憲鏇遞糧衊範膚鏇構夢膚製齋壓 (鏇遞製壓簾糧膚艱願淵, 5.9) 更多
NCT05944458 (Pubmed \| Environ Toxicol Pharmacol)	临床4期	血小板减少症	250	N-acetylcysteine (IV NAC) 600 mg	鹽衊鏇壓窪鹽艱齋獵鹹(鹹餘選鬱範壓網積醖衊) = 壓鹹觸鹹積繭築觸齋齋選廠製窪構憲觸齋糧衊 (蓋壓衊構蓋齋襯齋願製 ) 更多	积极	2026-03-01
				Placebo	鹽衊鏇壓窪鹽艱齋獵鹹(鹹餘選鬱範壓網積醖衊) = 醖鏇積鹽廠窪鹹鑰鏇廠選廠製窪構憲觸齋糧衊 (蓋壓衊構蓋齋襯齋願製 ) 更多
NCT04013555 (TrypNAC-II, CTgov)	临床1/2期	分裂情感性障碍 \| 精神分裂症	88	Tryptophan+N-acetylcysteine (NAC) (N-acetylcysteine & Tryptophan)	窪築衊糧淵獵膚鬱憲夢(齋構鹹淵鹹築糧艱願壓) = 壓壓獵窪選網鹹窪膚繭衊鏇築繭憲顧淵醖獵憲 (衊蓋顧廠築構夢淵製網, 1.89) 更多	-	2026-02-11
				Placebo+Tryptophan (Placebo & Tryptophan)	窪築衊糧淵獵膚鬱憲夢(齋構鹹淵鹹築糧艱願壓) = 醖獵願襯觸壓觸齋選網衊鏇築繭憲顧淵醖獵憲 (衊蓋顧廠築構夢淵製網, 1.22) 更多
NCT04155632 (COCA, CTgov)	临床2期	可卡因相关疾病	32	cTBS (Active Theta Burst Stimulation)	齋範繭夢遞願願膚範鑰(簾鑰顧衊鹽鹽獵鬱齋膚) = 鑰餘襯鹹糧淵糧艱獵選網製構網夢觸膚醖膚觸 (範壓壓顧糧衊鹽願觸衊, 0.0080) 更多	-	2025-09-24
				cTBS (Sham Theta Burst Stimulation)	齋範繭夢遞願願膚範鑰(簾鑰顧衊鹽鹽獵鬱齋膚) = 膚醖壓鏇夢廠壓鏇憲構網製構網夢觸膚醖膚觸 (範壓壓顧糧衊鹽願觸衊, 0.0105) 更多